OVID Earnings Date: Nov 11, 2026 (Estimated) — Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is OVID's next earnings date?
Ovid Therapeutics Inc. (OVID) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $31,091.
How did OVID do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Ovid Therapeutics Inc. posted EPS of -$0.08 versus the -$0.12 estimate, a beat of 20.0%. Revenue was $733,000 against a $21,429 estimate. The stock's 1-day post-earnings move was +6.9%.
How much does OVID stock move after earnings?
OVID beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.0% (up or down) in the day after earnings.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.12 | -0.08 | +20.00% | $733,000 | ✅ Beat | +6.87% | +11.83% | +2.67% |
| 2026-05-12 | Q1 2026 | -0.11 | -0.12 | -9.09% | $0 | ❌ Miss | +2.87% | -13.62% | -18.28% |
| 2026-03-18 | Q4 2025 | -0.10 | 0.06 | +160.00% | $718,000 | ✅ Beat | +14.43% | +20.40% | +39.30% |
| 2025-11-12 | Q3 2025 | -0.15 | -0.17 | -13.33% | $132,000 | ❌ Miss | -2.22% | -2.22% | +22.22% |
| 2025-08-13 | Q2 2025 | -0.15 | -0.06 | +60.00% | $6.3M | ✅ Beat | +56.86% | +71.85% | +128.52% |
| 2025-03-11 | Q4 2024 | -0.17 | -0.13 | +23.53% | $76,000 | ✅ Beat | +0.08% | -4.80% | -47.92% |
| 2024-11-12 | Q3 2024 | -0.19 | -0.20 | -5.26% | $173,000 | ❌ Miss | -8.82% | -23.53% | -19.85% |
| 2024-08-13 | Q2 2024 | -0.22 | 0.12 | +154.55% | $169,000 | ✅ Beat | +3.96% | +34.93% | +32.56% |
Showing last 8 quarters.